Lindy Biosciences has raised $150,000, according to a filing with the Securities and Exchange Commission.

The money was raised by a single investor.

The Durham-based company produces development-stage protein therapeutic formulations.

Its core technology, microglassification, produces spherical, dense, stable particles of a therapeutic protein, ideal for solid injectable formulations such as high-concentration suspensions or encapsulation for controlled release.

Lindy is developing high-dose suspension of protein suitable for subcutaneous injection, which will decrease administration costs, increase patient costs, increase patient comfort and compliance, and enable high-dose molecules to reach the market.

The company is led by Chief Executive Officer Deborah Bitterfield.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.